Novo NordiskNVO
NVO
About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 72,000
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 690 | Existing positions reduced: 637
0.45% less ownership
Funds ownership: 10.31% [Q2] → 9.86% (-0.45%) [Q3]
4% less funds holding
Funds holding: 1,831 [Q2] → 1,749 (-82) [Q3]
21% less capital invested
Capital invested by funds: $49.8B [Q2] → $39.5B (-$10.3B) [Q3]
32% less call options, than puts
Call options by funds: $791M | Put options by funds: $1.16B
33% less funds holding in top 10
Funds holding in top 10: 87 [Q2] → 58 (-29) [Q3]
36% less first-time investments, than exits
New positions opened: 148 | Existing positions closed: 230
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$156
43%
upside
Avg. target
$159
46%
upside
High target
$160
47%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Louise Chen 33% 1-year accuracy 40 / 121 met price target | 47%upside $160 | Overweight Reiterated | 6 Nov 2024 |
BMO Capital Evan David Seigerman 22% 1-year accuracy 4 / 18 met price target | 43%upside $156 | Outperform Maintained | 17 Oct 2024 |
Cantor Fitzgerald Louise Chen 33% 1-year accuracy 40 / 121 met price target | 47%upside $160 | Overweight Reiterated | 10 Oct 2024 |
Cantor Fitzgerald Louise Chen 33% 1-year accuracy 40 / 121 met price target | 47%upside $160 | Overweight Reiterated | 20 Sept 2024 |
Cantor Fitzgerald Louise Chen 33% 1-year accuracy 40 / 121 met price target | 47%upside $160 | Overweight Reiterated | 16 Sept 2024 |
Financial journalist opinion
Based on 97 articles about NVO published over the past 30 days
Positive
Zacks Investment Research
4 hours ago
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neutral
Reuters
5 hours ago
Novo Nordisk to cut US list prices of two insulin products by more than 70%
Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.
Positive
Investopedia
1 day ago
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday.
Positive
Barrons
1 day ago
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
Positive
CNBC
1 day ago
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings suggest Zepbound may be a superior treatment for weight loss, helping patients with obesity or who are overweight lose 20.2% of their body weight on average after 72 weeks.
Positive
Reuters
1 day ago
Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln
COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.
Positive
See It Market
2 days ago
Novo-Nordisk Stock (NVO), An Investors Love Story
Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. However, the Danish pharmaceutical Novo Nordisk began because of more personal reasons.
Positive
Benzinga
2 days ago
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
On Tuesday, Defiance ETFs introduced NVOX, the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S NVO.
Neutral
GlobeNewsWire
2 days ago
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting
Bagsværd, Denmark, 3 December 2024 – Novo Nordisk today announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California.
Positive
Proactive Investors
2 days ago
Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why
Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan's latest research. With concerns over US drug pricing policies easing and significant patent expirations on the horizon, the focus shifts to pipeline progress to drive growth, the American investment bank reckons, And it says Novo Nordisk (NYSE:NVO) and AstraZeneca PLC (LSE:AZN) are set to lead the way, bolstered by strong mid-term growth and promising news flow.
Charts implemented using Lightweight Charts™